Ph.D. , Molecular Biology, University of Maryland
Research Associate , Molecular Genetics Section, National Cancer Institute, NIH, Bethesda, Maryland.
Post-Doctoral Fellow , Mammalian Genetics Laboratory, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland

Dr. Shaughnessy's research interests are in the genetics of hematopoietic cell development. His current research is focused on the genetics of multiple myeloma.

Dr. Shaughnessy spent six years as a graduate student with Dr. Michael Potter at the National Cancer Institute's (NCI) Laboratory of Genetics where he focused on the use of a mouse model system to study the molecular mechanisms of myeloma. After a three-year postdoctoral fellowship in the Laboratory of Mammalian Genetics at the NCI Frederick Cancer Research and Development Center, where he focused on myeloid leukemia development, he joined the faculty of UAMS and the Myeloma and Transplantation Research Center in 1997.

In March of 2000 Dr. Shaughnessy became director of the new Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics. In addition to using cutting edge microarray technology in the analysis of myeloma, the laboratory is working toward the identification and characterization of myeloma tumor suppressor genes on chromosome 13.

Selected Publications

Wu K, Orme L, Shaughnessy J , Jacobson J, Barlogie B, and Moore MAS. Telomerase and Telomere Length in Multiple Myeloma: Correlations with Disease Heterogeneity, Cytogenetic Status and Overall Survival . Blood, 101:4982-4989 (2003)

Tarte K, De Vos J, Zhan F, Klein B, and Shaughnessy J. Gene Expression Profiling of Plasma Cells and Plasmablasts: Toward a Better Understanding of the Late Stages of B-Cell Differentiation. Blood, 102:592-600 (2003)

Shaughnessy J. Microarray Profiling of Multiple Myeloma. Int J. Haematol. 77:213-225 (2003)

Shaughnessy J and Barlogie B. Interpreting the Molecular Biology and Clinical Behavior of Multiple Myeloma Through Global Gene Expression Profiling. Immunol. Rev.194:140-63 (2003)

Shaughnessy J Jr . Primer On Medical Genomics. Part IX: Scientific and Clinical Applications of DNA Microarrays-Multiple Myeloma As A Disease Model. Mayo Clin Proc. 8:1098-109 (2003)

Zhan F, Barlogie B, and Shaughnessy J . Toward the Identification Distinct Molecular and Clinical Entities of Multiple Myeloma Using Global Gene Expression Profiling. Semin. Hematol. 40:308-20 (2003)

Tian E, Zhan F, Walker R, Rasmussan E, Ma Y, Barlogie B, Shaughnessy J. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N Eng J Med. 349:2483-2494 (2003)

Shaughnessy J , Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Jacobson J, Crowley J, Tricot G. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with Toal Therapy I; interpretation in the context of global gene expression. Blood, 101:3849-3856. (2003)

Shaughnessy J , Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cyotogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Hem, 120:44-52. (2003)